Clinical Trials Logo

Filter by:
NCT ID: NCT05880082 Enrolling by invitation - Clinical trials for Esophageal Squamous Cell Carcinoma

PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer

PPIO-004-EC001
Start date: April 13, 2023
Phase: Phase 2
Study type: Interventional

The goal of this observational study is to learn about in potential operable esophageal cancer patients (cT1-2N + M0 and cT3NanyM0) receiving neoadjuvant therapy. The main questions it aims to answer are: Objective response rate, Major pathological response rate. Participants will receive two to four cycles of tislelizumab plus albuminpaclitaxel and platinum-based therapy

NCT ID: NCT05875558 Enrolling by invitation - Clinical trials for Hepatocellular Carcinoma

M-TACE Treatment for Unresectable Hepatocellular Carcinoma

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

This study aims to investigate the safety and efficacy of transarterial chenmoembolization(TACE) combined with microspheres for unresectable hepatocellular carcinoma(HCC).

NCT ID: NCT05872828 Enrolling by invitation - Liver Cancer Clinical Trials

Cross-sectional Study of Chinese Liver Cancer Patients

Start date: April 1, 2023
Phase:
Study type: Observational [Patient Registry]

The goal of this cross-sectional study is to investigate the prevalence and risk factors of anxiety and depression and their relationships with immune functions and quality of life among liver cancer patients in the COVID-19 pandemic era. The objectives of this study are: 1. To examine the prevalence of anxiety and depression among patients with liver cancer during the COVID-19 pandemic. 2. To identify risk factors associated with anxiety and depression among these patients. 3. To determine the association between anxiety, depression, immune function, and quality of life among liver cancer patients. Participants will be asked to fill a digital questionnaire.

NCT ID: NCT05865925 Enrolling by invitation - Clinical trials for Advanced Solid Tumors

Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors

Start date: April 22, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open, dose escalation, single and multiple administration phase Ⅰ/Ⅱ clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), and primary clinical efficacy of LY01616 in patients with advanced solid tumors

NCT ID: NCT05861869 Enrolling by invitation - Clinical trials for Membranous Nephropathy - PLA2R Induced

Clinical Trial of PLA2R-IgG4 Detection Kit (Time-resolved Fluorescence Immunoassay)

Start date: May 4, 2023
Phase:
Study type: Observational

The goal of this observational clinical trial is to compare assessment reagents with clinical diagnostic criteria in patients with membranous nephropathy. The main questions it aims to answer are: - Evaluating the sensitivity and specificity of the test reagent in the diagnosis of membranous nephropathy. - Evaluating whether the clinical diagnostic performance of the test reagent meets the requirements for auxiliary diagnosis of membranous nephropathy. Participants will provide approximately 4ml of blood. Researchers will compare the levels of anti-PLA2RIgG4 in patients with membranous nephropathy and patients with other renal diseases,to see if there is a significant difference.

NCT ID: NCT05844813 Enrolling by invitation - Clinical trials for Retroperitoneal Sarcoma

Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma

NATARS
Start date: November 1, 2022
Phase: Phase 4
Study type: Interventional

The goal of this clinical trial is to explore the potential survival benefits of neoadjuvant chemotherapy combined with target treatments followed by radical surgery in patients with primary high-risk/grade retroperitoneal sarcoma. The main questions it aims to answer are: - Whether the 1,3-year progression-free survival time(PFS) is prolonged in the neoadjuvant therapy group, compared with the surgery-only group. - The Overall survival time in the two groups. - The safety and tolerance in the neoadjuvant therapy group. Participants will be allocated into two groups once they meet the inclusion criteria. - Surgery-only Group: Patients will directly undergo surgeries after the confirmation of diagnosis through pre-operative biopsy. - Neoadjuvant therapy group: Patients will receive the neoadjuvant chemotherapy combined with target treatment for three circles before the following sarcoma resectional surgeries.

NCT ID: NCT05837156 Enrolling by invitation - Nausea and Vomiting Clinical Trials

A Clinical Study to Evaluate Cyclopofol Injection for the Prevention of Postoperative Nausea and Vomiting

Start date: August 2, 2023
Phase: Phase 1
Study type: Interventional

This study uses cyclopropofol as a positive control and adopts a large sample, multicenter, randomized, single-blind, positive parallel control test design to explore the clinical application value of cyclopropofol in preventing postoperative nausea and vomiting.

NCT ID: NCT05836909 Enrolling by invitation - Clinical trials for Hypercholesterolemia

Regulation of Lipid Metabolism in Guangzhou Individuals With Dyslipidemia by Red Yeast Rice, Phytosterol Esters and Lycopene

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the effect of using red yeast rice, phytosterol esters and lycopene in combination for 12 weeks on improving the glycolipid metabolism of Guangzhou individuals with dyslipidemia. Our hypothesis is that when compared with placebo, red yeast rice, phytosterol esters and lycopene together as supplements would lead to greater improvements in lipid metabolism (including lipid profiles and parameters ) in participants after 12 weeks.

NCT ID: NCT05833802 Enrolling by invitation - Breast Cancer Clinical Trials

Computation Prediction of Drug Response Based on Omics Data

Start date: February 15, 2023
Phase:
Study type: Observational

The goal of this observational study is to assess the performance of computational medicine technology in predicting patients response to anticancer drugs based on omics data.The main question it aims to answer is test consistency between the computing drug response and the response of real-world clinical trials. Participants will take part in silico.

NCT ID: NCT05824871 Enrolling by invitation - Clinical trials for Rifampicin-resistant Tuberculosis

Sudapyridine (WX-081) in RR/MDR/XDR-tuberculosis Patients

WISH
Start date: September 2, 2022
Phase: Phase 3
Study type: Interventional

The objective of this study is to demonstrate that the antibacterial activity of Sudapyridine (WX-081) is not inferior to Bedaquiline when added to a Background Regimen (BR) for treatment of rifampicin- resistant TB. Also, safety and clinical outcome will be evaluated.